Evidence map›Paper›PMID 25637741›Full record

ArticleRedox biology2015

Inhibition of the phospholipase A2 activity of peroxiredoxin 6 prevents lung damage with exposure to hyperoxia.

Bavneet Benipal, Sheldon I Feinstein, Shampa Chatterjee, Chandra Dodia, Aron B Fisher

Open access · goldAbstract read
In one paragraph

Article in Redox biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. A Peptide Inhibitor of Peroxiredoxin 6 Phospholipase AAntioxidants (Basel, Switzerland) · 2021
    Article
  8. Review
  9. Article
  10. Article
  11. Genetic inactivation of the phospholipase AAmerican journal of physiology. Lung cellular and molecular physiology · 2019
    Article
  12. Article
  13. The Role of Peroxiredoxin 6 in Cell Signaling.Antioxidants (Basel, Switzerland) · 2018
    Review
  14. The phospholipase AJournal of lipid research · 2018
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Bavneet BenipalInstitute for Environmental Medicine and Department of Physiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Sheldon I FeinsteinInstitute for Environmental Medicine and Department of Physiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Shampa ChatterjeeInstitute for Environmental Medicine and Department of Physiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Chandra DodiaInstitute for Environmental Medicine and Department of Physiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Aron B FisherInstitute for Environmental Medicine and Department of Physiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: abf@mail.med.upenn.edu.
Institute for Environmental Management · US

Funding

Translational Research Support CoreP30ES013508 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI Trevor M Penning · 2006 to 2026
$35.3M
Role of Peroxiredoxin 6 in the Repair of Peroxidized Cell MembranesR01HL102016 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI FISHER, ARON B. · 2010 to 2018
$4.6M
Role of Prdx6 in the activation of NADPH oxidaseR01HL105509 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI FISHER, ARON B. · 2011 to 2015
$2.6M
NHLBI NIH HHS HL-R-01-105509NHLBI NIH HHS R01 HL102016NHLBI NIH HHS R01 HL105509NIEHS NIH HHS P30 ES013508
6 · The paper itself

Abstract

Lung injury associated with hyperoxia reflects in part the secondary effects of pulmonary inflammation and the associated production of reactive oxygen species due to activation of NADPH oxidase, type 2 (NOX2). Activation of NOX2 requires the phospholipase A2 (PLA2) activity of peroxiredoxin 6 (Prdx6). Therefore, we evaluated whether blocking Prdx6 PLA2 activity using the inhibitor MJ33 would be protective in a mouse model of acute lung injury resulting from hyperoxic exposure. Mice were treated with an intraperitoneal injection of MJ33 (2.5nmol/g body weight) at the start of exposure (zero time) and at 48h during continuous exposure to 100% O2 for 80h. Treatment with MJ33 reduced the number of neutrophils and the protein content in the fluid obtained by bronchoalveolar lavage, inhibited the increase in lipid peroxidation products in lung tissue, decreased the number of apoptotic cells in the lung, and decreased the perivascular edema associated with the 80h exposure to hyperoxia. Thus, blocking Prdx6 PLA2 activity by MJ33 significantly protected lungs against damage from hyperoxia, presumably by preventing the activation of NOX2 and the amplification of lung injury associated with inflammation. These findings demonstrate that MJ33, a potent inhibitor of Prdx6 PLA2 activity, can protect mouse lungs against the manifestations of acute lung injury due to oxidative stress.

Indexed as

Acute Lung InjuryAnimalsApoptosisBronchoalveolar Lavage FluidGene Expression RegulationGlycerophosphatesHyperoxiaInjections, IntraperitonealLipid PeroxidationLungMaleMembrane GlycoproteinsMiceMice, Inbred C57BLNADPH Oxidase 2NADPH Oxidases1-hexadecyl-3-trifluoroethylglycero-sn-2-phosphomethanolCybb protein, mouseGlycerophosphatesMembrane GlycoproteinsNADPH Oxidase 2NADPH OxidasesOxygenPeroxiredoxin VIPhospholipase A2 InhibitorsPhospholipases A2Prdx6 protein, mouseReactive Oxygen SpeciesAcute lung injuryInflammationLipid peroxidationMJ33Oxidative stress

Identifiers

PMID25637741
PMCPMC4803794
OpenAlexW2009895452

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.